We have developed an in vitro human vaginal epithelial cell (EC) model using the innovative rotating wall vessel (RWV) bioreactor technology that recapitulates in vivo structural and functional properties, including a stratified squamous epithelium with microvilli, tight junctions, microfolds, and mucus. This three-dimensional (3-D) vaginal model provides a platform for high-throughput toxicity testing of candidate microbicides targeted to combat sexually transmitted infections, effectively complementing and extending existing testing systems such as surgical explants or animal models. Vaginal ECs were grown on porous, collagen-coated microcarrier beads in a rotating, low fluid-shear environment; use of RWV bioreactor technology generated 3-D vaginal EC aggregates. Immunofluorescence and scanning and transmission electron microscopy confirmed differentiation and polarization of the 3-D EC aggregates among multiple cell layers and identified ultrastructural features important for nutrient absorption, cell-cell interactions, and pathogen defense. After treatment with a variety of toll-like receptor (TLR) agonists, cytokine production was quantified by cytometric bead array, confirming that TLRs 2, 3, 5, and 6 were expressed and functional. The 3-D vaginal aggregates were more resistant to nonoxynol-9 (N-9), a contraceptive and previous microbicide candidate, when compared to two-dimensional monolayers of the same cell line. A dose-dependent production of tumor necrosis factor-related apoptosis-inducing ligand and interleukin-1 receptor antagonist, biomarkers of cervicovaginal inflammation, correlated to microbicide toxicity in the 3-D model following N-9 treatment. These results indicate that this 3-D vaginal model could be used as a complementary tool for screening microbicide compounds for safety and efficacy, thus improving success in clinical trials.
INTRODUCTION
Vaginal epithelial cells (ECs) provide the first line of defense for women exposed to sexually transmitted infections (STI) [1, 2] . These cells can provide both structural and immunological defense mechanisms against STI pathogens. In vivo, vaginal ECs are characterized as sheets of multicellular stratified squamous epithelia that exhibit tissue-specific protein expression patterns between the basal and suprabasal surfaces, produce mucus glycoproteins that aid in enzymatic and pathological defense, and exhibit distinct morphological features like microfolds, microridges, and cell-cell adhesion structures [3] [4] [5] [6] [7] . These ECs also play a critical role in immunological response to pathogens and pathogen-associated molecular patterns (PAMPs) through toll-like receptor (TLR) signaling cascades, cytokine and chemokine production, as well as immune cell recruitment and activation [1, 2, 8, 9] . All of these features are physiologically relevant attributes of vaginal ECs that should be present in an organotypic vaginal EC model developed for microbicide and/or STI research.
Microbicides are agents that can be applied topically to the vagina or rectum and provide a promising approach for STI prevention. These compounds can act directly on the STI pathogen, or they can act indirectly by inducing innate immune responses in the genital epithelia and/or by recruiting immune cells to the site of infection. In addition to the direct or indirect mechanisms of action that a particular microbicide may exhibit, it is equally crucial that the compound does not cause uncontrolled inflammation, toxicity, or damage to the integrity of the vaginal epithelia [10] [11] [12] .
Nonoxynol-9 (N-9) is the active ingredient in the over-thecounter spermicide Conceptrol, and it has gained particular attention after it showed anti-HIV activity both in vitro and in animal models. Unfortunately, this compound subsequently failed clinical trials and, in some cases, increased the incidence of HIV transmission [13, 14] . It has been hypothesized that increased HIV transmission after N-9 treatment was caused by the disruption of the mucosal epithelial barrier and integrity, recruitment of HIV-susceptible immune cells, genital EC inflammation, and/or microbicide-induced changes in the natural vaginal flora [12] [13] [14] . Because N-9 was shown to disrupt the human vaginal EC barrier and has been studied in humans in vivo, it has become an excellent tool for validating cell culture, tissue explants, and animal models for their relevance as microbicide safety and efficacy models [13, 15] .
Several studies have indicated that various primary and immortalized cell lines grown as traditional monolayers on impermeable plastic surfaces or suspension cultures are significantly more susceptible to N-9 toxicity than surgical explants and various animal models, which more closely mimic the physiological features of human reproductive tract tissues [12, 16, 17] . As such, human and animal explants from vaginal and cervical biopsies have become a primary in vitro method for microbicide evaluation [11, 18] . Several caveats of these explant models have been described and include a progressive deterioration of tissue architecture in explanted tissues as well as limitations with tissue availability, variability between samples, and the requirement for Institutional Review Board approval [11, 17] . While these explant models do provide a powerful tool for evaluating microbicide safety and efficacy in the female reproductive tract, they are not an ideal model for high-throughput evaluations.
High-throughput screening provides the means to test cellular viability in response to a greater number of compounds simultaneously in addition to evaluating signature biomarkers, which have become increasingly important molecules for diagnosing cervicovaginal inflammation. There have been a number of biomarkers implicated in cervicovaginal inflammation. Among these biomarkers, we evaluated the endogenous antagonist of interleukin-1 (IL1RN or IL-1RA), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma (IFNG), interleukin 6 (IL6), IL8 (or CXCL8), regulated upon activation, normal T-cell expressed and secreted (RANTES, official symbol CCL5), and interferon-inducible protein 10 (IP-10, official symbol CXCL10) [2, 8, 11, [19] [20] [21] . Cytokine-signaling cascades can contribute to proinflammatory and anti-inflammatory immune responses as well as immune cell recruitment and activation. These biomarkers have provided valuable screening tools for microbicide studies and are particularly well suited for high-throughput in vitro evaluations.
Several of these cytokines can be triggered by TLR activation from microbial ligands or synthetic TLR agonists. These TLRs can play an integral role in sensing both pathogens and some microbicide compounds, and have been implicated as key players in mucosal homeostasis [1, 10, 22] . TLR2, 3, 5, and 6 have been shown to be highly expressed and functionally bioactive in vaginal ECs [1, [23] [24] [25] . Therefore, candidate microbicide screening should include analysis of TLRmediated cytokine production, especially since a recent report by Trifonova et al. [10] demonstrated that a class of microbicides could inhibit TLR responsiveness in genital epithelia.
In addition to the in vitro methods available for microbicide evaluation, animal models play an integral role in the microbicide development pipeline. The standardized model for vaginal toxicity studies is the rabbit vaginal irritation model; however, additional microbicide evaluation studies have been conducted in mouse and macaque animal models [12, [26] [27] [28] . While these animal models provide valuable tools for evaluating the histopathological, systemic, and immunological effects of microbicides, they may not accurately predict human toxicity due to species variations and are not ideal platforms for high-throughput toxicity testing.
Our collaborative group has utilized the rotating wall vessel (RWV) bioreactor technology to create several three-dimensional (3-D) cell culture models (i.e., gastrointestinal, lung, colon, placental, and neuronal) that exhibit physiologically relevant features observed in vivo [29] [30] [31] [32] [33] . This technology has produced 3-D models, grown in a physiological, low fluid shear environment, that have been shown to mimic key aspects of the parental tissue in vivo and that have been applied to study bacterial and viral pathogenesis, tumorogenesis, osteogenesis, hormone and protein expression, etc. [34] [35] [36] [37] . The RWV bioreactor technology exposes cell cultures to gravitational, centrifugal, and Coriolis forces, causing a gradual sedimentation of the cells as the vessel turns; this controlled rotation minimizes detrimental shear forces and allows the cells to form 3-D, tissue-like aggregates [38, 39] . To our knowledge, this is the first report to exploit the RWV technology to develop and characterize a 3-D organotypic vaginal EC model for high-throughput analysis of candidate microbicides and STI pathogenesis research specific to the vaginal EC microenvironment. Overall, this in vitro model preserves the functional architecture of the parental vaginal tissue, yet retains the ease and accessibility of an immortalized vaginal EC line.
MATERIALS AND METHODS

Mammalian Cell Culture
Vaginal EC monolayers. The immortalized vaginal EC (V19I) line was kindly provided by Dr. Richard Pyles, and cells were cultured as previously described [1, 25, 40] . V19I monolayers were grown in T-150 flasks (BD Falcon; BD Biosciences, San Jose, CA), released with 0.25% trypsin (Mediatech, Inc., Manassas, VA), and enumerated as previously described [1] . Cell quantification was performed either manually with a hemacytometer or automatically with the Countess automated cell counter (Invitrogen, Carlsbad, CA). Confluent vaginal EC monolayers (passages [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] were used for all the experiments.
Three-dimensional vaginal EC model. V19I cell suspensions (3 3 10 6 cells) were mixed with 0.3 grams of type 1 collagen-coated dextran microcarrier beads (Cytodex-3; Sigma-Aldrich, St. Louis, MO). Microcarrier beads were autoclaved in sterile Dulbecco PBS (DPBS) (Invitrogen) (1108C, 20 min) and were allowed to swell at ambient temperature for at least 3 days before being combined with the V19I cell suspensions. Cells/beads were seeded (Day 0) in 55 ml of media in the rotating wall vessel (RWV; Synthecon, Inc., Houston, TX), which was allowed to incubate prior to rotation for 0.5 h at 378C and 5% CO 2 and was subsequently cultured at a rate of approximately 20 rotations per min. Images and technical descriptions of RWV bioreactors have been reviewed by Navran [39] . Culture media was changed 96 h after the RWV was seeded, every 48 h until Day 12, and then every 24 h until the aggregates were ready to harvest (Days 39-42). In addition to changing the media, an additional 1 3 10 6 V19I cells were added to the rotating culture once an initial layer of cells had grown on the beads (;Day 21) to ensure a more uniform culture. Samples of the 3-D vaginal aggregates (500 ll) were monitored frequently by differential interference contrast (data not shown), confocal, and electron microscopy analyses. After 39-42 days rotating in the RWV culture, all of the 3-D cell aggregates were harvested and either fixed for morphological and histological analysis, or plated in a 24-well plate for cell treatments/ stimulation experiments. A single RWV (55-ml volume) consistently yielded two 24-well plates with at least 2 3 10 4 cells/well. Prior to use in all the assays, cell viability was determined using trypan blue.
Electron Microscopy
Primary fixation. The 3-D vaginal aggregates were fixed in fresh, primary fixative (2% glutaraldehyde/2% formaldehyde (Electron Microscopy Sciences, Hatfield, PA) in DPBS for 0.5 h at ambient temperature and were incubated in the primary fixative for an additional 24 h at 48C. The fixative was removed, and the aggregates were washed three times in DPBS. Aggregates were then fixed/stained in 1% osmium tetroxide (OsO 4 ) (Electron Microscopy Sciences) in double-distilled H 2 O (ddH 2 O) for 1 h at ambient temperature. The aggregates were then washed three times in ddH 2 O. All subsequent fixation and staining procedures described were performed at ambient temperature.
Transmission electron microscopy secondary fixation, sample preparation, and microscopy. For transmission electron microscopy (TEM) studies, aggregates were then stained en bloc with 1% uranyl acetate (Electron Microscopy Sciences) in ddH 2 O for 1 h. The aggregates were washed again three times in ddH 2 O. Samples were then dehydrated in a seven-step series of ethanol solutions, followed by a 10-min equilibration in 1:1 ethanol:acetone. The aggregates were then stained en bloc with 1% (saturated) lead acetate (Malliinckrodt Baker, Phillipsburg, NJ) diluted in the ethanol/acetone solution for an additional 1 h. The aggregates were then rinsed twice in the ethanol/ acetone solution, followed by two dehydration steps in 100% acetone. The acetone was removed, and the aggregates were placed in a progression of Spurr's resin (Electron Microscopy Sciences)/acetone solutions, during which time the resin concentration was increased every 12 h. Aggregates were then removed from the glass jars and placed into vertical conical molds in 100% Spurr's resin that was allowed to polymerize in a 608C oven for 24 h. Once the blocks containing cells of interest were identified, ultrathin sections (80 nm) were cut with a diamond knife (Diatome, Hatfield, PA) on a Leica Ultracut R microtome and were placed on formvar-coated 200-mesh copper grids (Electron Microscopy Sciences). Samples were imaged with a Philips CM12 Transmission Electron Microscope, and images were acquired using a Gatan 791 CCD camera and software (Gatan, Pleasanton, CA).
Scanning electron microscopy sample preparation and microscopy. For scanning electron microscopy (SEM) studies, aggregates were dehydrated in a series of acetone solutions, dried with a CPD020 critical point dryer (Balzers, Wiesbaden, Germany), and sputter-coated for 7 min with platinum in a Technics Hummer II sputter coater (Technics, Alexandria, VA). Samples were imaged with a Leica Cambridge Stereoscan 360 FE scanning electron microscope (Leica Cambridge Co., Cambridge, U.K.) using the EDS 2006 software (IXRF Systems Inc., Houston, TX).
Immunofluorescence
Sample preparation and microscopy. 0 ,6-diamidino-2-phenylindole (Molecular Probes, Invitrogen). Optical sections (1-2 lm) through the z-plane of the cell layers were obtained using a Zeiss LSM 5 DUO laser scanning confocal microscope and analyzed using the Zeiss LSM browser software package (Carl Zeiss, Thornwood, NY). Z-Stack images were reconstructed from fifty to one hundred 1-2 lm optical sections using the Zeiss LSM software package (Carl Zeiss). All immunofluorescence results were verified in multiple batches of 3-D vaginal EC aggregates.
Nonoxynol-9 Treatment and Cell Viability Assay
Cell treatment procedure. Three-dimensional vaginal EC model aggregates were removed from the RWV bioreactors and distributed evenly in 24-well tissue culture plates (BD Falcon; BD Biosciences) for testing at a density of at 2 3 10 4 cells/well. Monolayers were seeded into separate 24-well plates at the same density. Two wells of each plate were trypsinized (0.25%; Mediatech, Inc.) and enumerated by trypan blue (Mediatech, Inc.) exclusion to determine initial cell viability/concentration. Nonoxynol-9 (Ortho Options Conceptrol; McNeil-PPC, Inc., Fort Washington, PA) was added to duplicate wells at 20, 100, and 500 lg/ml, all diluted in sterile DPBS. In addition, sterile DPBS treatments were performed and used as a negative control. All the structural and functional characterization was performed within 48 h after removal from the RWV; however, aggregates retain structural morphology and viability for at least 72 h postplating.
Cell viability assay. Cell supernatants (120 ll) were collected from each well at 1.5, 4, 8, and 24 h, and analyzed by cytometric bead array (CBA) (BioPlex; Bio-Rad, Hercules, CA) for cytokine/chemokine production. In addition, DPBS-and N-9-treated wells were harvested, trypsinized, and enumerated by trypan blue (Mediatech, Inc.) exclusion to determine the cell viability for each time point.
TLR Agonist Treatments and Cytokine Quantification
TLR agonists. The 3-D vaginal EC aggregates or monolayers were plated at 2 3 10 4 cells/well in 24-well tissue culture treated plates (BD Falcon; BD Biosciences). TLR agonists were added to vaginal ECs at the following concentrations: FSL-1 (InvivoGen, San Diego, CA), a synthetic lipoprotein derived from Mycoplasma salivarium and a TLR2/6 heterodimer agonist (0.1 lg/ml); polyinosinic:polycytidylic acid (PIC) (InvivoGen), a synthetic form of double-stranded RNA and a TLR3 agonist (100 lg/ml); flagellin (FLAG) (InvivoGen), the major component of bacterial flagellar filaments and a TLR5 agonist (5 lg/ml); CL097 (InvivoGen), an imidazoquinoline compound with potent antiviral activity and a TLR7/8 agonist (10 lg/ml); and sterile DPBS. Cell supernatants (120 ll) were collected from each well at 24 h poststimulation and were frozen at À208C until analysis by CBA to determine TLR activity (i.e., cytokine/chemokine production).
Cytokine/chemokine quantification. Cytokine analysis was determined by CBA. A custom human CBA kit was constructed that contained the following targets: TRAIL, IL1RN, IL6, IL8, RANTES, IP-10, and IFNG (BioRad). Cytokine levels were quantified using the Bioplex-200 system and BioPlex 4.0 manager software (Bio-Rad).
Toxicity concentrations. Mean toxic concentration 50 (TC 50 ) values were displayed as the toxic concentration in lg/ml where 50% of the cells remained viable when visualized by trypan blue exclusion (Mediatech, Inc.). Cells treated with sterile DPBS and cell culture media alone were used as negative controls. TC 50 values for each time point were calculated manually using the Reed and Muench method [41] .
Statistical Analysis and Graphs
Statistical analyses and graphical representations were completed and produced, respectively, using Prism software (v4.0; GraphPad, San Diego, CA). One-tailed t-tests were employed. A P-value of ,0.05 was considered to be statistically significant.
RESULTS
Three-Dimensional Vaginal EC Model Development and Ultrastructural Morphology
Human vaginal ECs cultured in the RWV bioreactor under low fluid-shear conditions exhibited ultrastructural morphology consistent with mammalian vaginal tissue. The 3-D vaginal EC model progressively developed through two stages, early development and late development, each with its own distinct surface morphology. After 19-21 days in the rotating culture, SEM revealed microcarrier bead aggregates covered with a single monolayer of vaginal ECs (early development). This monolayer had surface characteristics remarkably similar to the early vaginal canal and fornix development (Days 2-7) of postnatal BALB/c mice examined by SEM [42, 43] . Vaginal ECs observed at this time point were of variable size and presented a convex apical cell shape covered with sparsely distributed microvilli (Fig. 1, A and C) . After approximately 20 additional days in the rotating culture (Days 39-42), 3-D vaginal EC aggregates demonstrated surface morphology of a fully polarized and differentiated vaginal epithelium (late development) (Fig. 1, B and D) . Surface characteristics included flattened cell layers of connecting, polygonal apical ECs (typical of a stratified squamous epithelial tissue), densely packed lawns of microvilli of various lengths, vaginal microfolds (i.e., rugae), as well as numerous microridges and secretory vesicles/mucus deposits between adjacent cells and on the apical cell surface (Fig. 2, A, C, E, and G) . Representative SEM images of human vaginal tissue displaying these ultrastructural features (i.e., flattened polygonal apical ECs, microfolds, and microridges) are provided in Supplemental Figure S1 (available online at www.biolreprod.org). Collectively, these characteristics of this 3-D vaginal EC model correspond to surface features observed by SEM in the late vaginal canal and fornix development (Days 21-78) of postnatal BALB/c mice, human neovaginal tissue created for females with Mayer-Rokitansky-Kuster-Hauser syndrome, and, most notably, normal human vaginal tissue (Supplemental Figure S1 ) [5-7, 42, 43] .
In addition to examining the surface morphology of our 3-D vaginal EC model, TEM was performed on ultrathin sections in order to visualize the internal ultrastructural features of this model. Internal secretory vesicles were observed primarily in cells on the apical cell surface, suggesting these cells are directly involved in mucus secretion (Fig. 2B) . Long, 3-D ORGANOTYPIC HUMAN VAGINAL CELL MODEL protruding microvilli were also observed primarily on the apical cell surface of the 3-D model; however, short residual microvilli, also referred to as cytoplasmic processes, were observed between adjacent cells near both the apical and the basolateral surfaces (Fig. 2, F and H) [44] . Cellular junctions were also observed throughout the 3-D model tissue (Fig. 2D) . In contrast, neither SEM nor TEM revealed long, protruding microvilli or microfolds on the apical surface of confluent vaginal ECs grown on transwell filters, which was verified by observing a significant increase in transepithelial electrical resistance (data not shown). All of these ultrastructural features are remarkably similar to and have been previously reported in SEM and/or TEM from in vivo dissections of mammalian vaginal tissue (e.g., mouse, rabbit, rhesus monkey, and human) [7, [42] [43] [44] [45] [46] . The expression and cellular localization of several important proteins were investigated by immunofluorescence. One important family of proteins in the female reproductive tract is the mucin (MUC) glycoprotein family. MUC1 is a transmembrane glycoprotein that exhibits both adhesive and antiadhesive properties, effectively creating a barrier against invading microbes at epithelial cell surfaces [47, 48] . MUC1 is also the most widely distributed mucin amongst various human mucosal tissues, including the female reproductive tract, and has been previously reported to be the highest expressed mucin in vaginal epithelial tissue [4, [47] [48] [49] [50] . Anti-MUC1 staining displayed intense fluorescence throughout the 3-D vaginal EC model, especially in the crevices and folds of the tissue (Fig.  3A) . This has previously been reported to be a region rich in mucin-like glycoproteins in stratified squamous epithelia [50] . The fluorescence intensity of this glycoprotein was lower in 2-D monolayers and its localization was cytoplasmically diffuse (Fig. 3D) . In addition to MUC1, the mucin glycoprotein MUC4 (which can be membrane-bound or in a soluble form) is the only other mucin that has been shown to be expressed in the human vaginal epithelium [49, 51] . MUC4 was expressed, albeit at low levels, in the 3-D vaginal EC model while no specific expression was detected in 2-D monolayers (Fig. 3, B and E, respectively). The expression of these two mucin proteins corresponds to previously published data detailing the tissue-specific mucin expression profiles of the female reproductive tract [4, 47, [49] [50] [51] . MUC5AC has previously been reported to be highly expressed in human endocervical tissue, but not in ectocervical or vaginal ECs [49] . MUC5AC expression was analyzed as a negative control and was determined to be negative in both the 3-D vaginal EC model and in 2-D monolayers (Fig. 3, C and F, respectively) .
The expression and localization of the following two junctional markers were also examined to determine differentiation of the 3-D vaginal EC model: the zona occludens protein, TJP1 (ZO-1), and the adhesive extracellular matrix constituent, E-cadherin (epithelial designation; member of the cadherin superfamily). These proteins are important adhesion molecules necessary for development of intercellular junctional complexes and maintenance of epithelial integrity [52, 53] . E- Cadherin and TJP1 were expressed at lower levels in the 2-D monolayers, and immunolocalization revealed the proteins were cytoplasmically diffuse and were not primarily localized to the plasma membrane as in differentiated tissues (Fig. 4, F and G). In contrast, both TJP1 and E-cadherin were highly expressed in the 3-D vaginal EC aggregates and exhibited a honeycomb pattern typical of fully differentiated epithelial cells (Fig. 4, A and B) [52, 53] . Finally, the expression and localization of the glycoproteins epithelial-specific antigen (ESA), CD1D, and the terminal differentiation marker, involucrin, were examined by immunofluorescence. ESA is a basolateral marker of most human epithelia and has been implicated in cell-cell adhesion processes [54, 55] . CD1D is a major histocompatibility complex-like glycoprotein that mediates the presentation of lipid and glycolipid antigens to natural killer T cells [56] . Kawana et al. have recently reported the robust expression of CD1D in both vaginal and ectocervical tissues within the female reproductive tract, but only low-level expression in endocervical on endometrial tissues [56] . Lastly, involucrin, a terminal differentiation marker of keratinocytes, has been shown by Fichorova et al. to be expressed in subpopulations of immortalized vaginal EC monolayers and on the surface of vaginal tissue [3] . Vaginal EC monolayers expressed little to no ESA or involucrin, but displayed positive expression for CD1D (Fig. 4, H-J) . Expression of ESA was identified throughout the 3-D vaginal EC layers, while involucrin and CD1D were both primarily localized to the cell surface (Fig. 4,  C-E) .
TLR Activity
Previously, we have shown that both primary and immortalized vaginal ECs express TLRs 1-6 at the highest levels as profiled by quantitative PCR and are highly responsive to agonists directed against TLRs 2, 3, 5, and 6 [1] . In addition, these studies have indicated that TLRs 7 and 8 are minimally expressed and are not consistently bioactive in vaginal ECs. In order to verify that TLRs 2, 3, 5, and 6 remained functionally responsive in our 3-D vaginal EC model and that there were no profound changes in TLR expression during 3-D development, vaginal cell aggregates were treated with TLR agonists (FSL-1, PIC, FLAG, and CL097). Cytokines IL6 and IFNG, the chemokines IL8 and CXCL10 (IP-10), and CCL5 (RANTES) were quantified by CBA and were found to be increased in concentration in the cell culture medium when cells were treated with FSL-1 (TLR2/6 agonist), PIC (TLR3 agonist), or FLAG (TLR5 agonist) (Fig. 5) . Conversely, treatment with CL097, a TLR 7/8 agonist, did not result in cytokine or chemokine levels higher than DPBS controls. These results indicate that the 3-D vaginal EC model retained TLR expression similar to primary and immortalized vaginal monolayers cells and that these TLRs retained functional bioactivity when cultured under rotating conditions [1] .
Nonoxynol-9 Toxicity and Cytokine Response
In order to examine the utility of our 3-D model as a platform for evaluating microbicide safety and efficacy, both 3-D vaginal EC aggregates and vaginal EC monolayers were treated with N-9 and examined for viability posttreatment (Fig.  6A) . TC 50 levels were determined for 1.5, 4, 8, and 24 h time points using the Reed and Muench calculation method [41] . TC 50 levels for the vaginal EC monolayers ranged between 9 lg/ml to 21 lg/ml and likewise did not decrease significantly during the times examined (Fig. 6B) . These TC 50 levels for the vaginal EC monolayers correspond to previous results of many various cell lines grown as traditional monolayers or suspension cell cultures [16] . On the contrary, TC 50 levels for the 3-D vaginal EC model ranged between 225lg/ml to 425lg/ml for the various time points and did not decrease significantly during the times examined (up to 24 h post-N-9 treatment). These results indicate that our 3-D vaginal EC model has a toxicity response to N-9 much more similar to surgical explant models than their monolayer counterparts [16] .
In addition to evaluating viability, cell supernatants from both the 3-D vaginal EC model and vaginal EC monolayers were examined for TRAIL and IL1RN production, both of which are biomarkers of cervicovaginal inflammation. The 3-D vaginal EC model produced higher levels of TRAIL and IL1RN after 24 h at all of the N-9 concentrations tested (10-1000 lg/ml) (Fig. 6, C and D) . While the cytokine levels between the 3-D vaginal EC model and the 2-D monolayers were not statistically significant, the higher levels expressed in 
DISCUSSION
There is an urgent need for the development of both new microbicide compounds and of new, biologically meaningful platforms in which to evaluate their safety and efficacy [17, 57] . An efficient and high-throughput method for screening candidate microbicides is an essential component of the developmental pipeline. The 3-D vaginal EC model described in this report provides an in vitro platform for microbicide evaluation and STI research that exhibits many of the physiologically relevant features of surgical explants and animal models, but is afforded the high-throughput capabilities of an immortalized human cell line.
Many publications have demonstrated that various types of mammalian cells can only differentiate when cultured under specific cell culture conditions; this concept holds true for human vaginal EC [38, 39, 58] . Although media conditions and growth factor supplements are important factors to consider for any cell culture line or model, additional emphasis can be placed on the extracellular environment in which the cells are grown and on the surface to which they adhere. Transwell filters, extracellular matrix formulations or gels, and the RWV bioreactor have all been used to induce terminal differentiation in a variety of cell types; however, use of the RWV bioreactor technology for tissue culture also mimics the nonstatic growth conditions that proliferating cells are subject to in the human body [38, 39, 58] . Using this RWV technology, we developed and characterized a 3-D vaginal EC model because traditional monolayer cultures have not demonstrated many of the ultrastructural features of human vaginal tissue and the microbicide and the STI communities still rely heavily on tissue explants and animal models for clinical pipeline studies [11, 12] .
Morphological analysis of our 3-D vaginal EC model demonstrated a remarkable resemblance to in vivo mammalian tissue, even at the high resolution provided by SEM and TEM analyses. These features included microvilli, tight junctions, microfolds, microridges, and secretory vesicles or mucus. Microfolds are often observed on the surface of cells where a protective layer is advantageous and function by holding mucus in place as well as aid in stabilizing and interlocking the cell layers. Typically these surface elaborations are observed in late proestrus and estrus [45] . The appearance and characterization of microfolds (or rugae) in this 3-D vaginal EC model may provide a particularly important feature for microbicide evaluation and STI research. For example, previous studies have illustrated that several vaginally applied microbicide candidates, tested in Chlamydia and herpes simplex virus type 2 (HSV-2) mouse challenge models, failed to penetrate the murine vaginal rugae [27, 59] . This incomplete distribution consequently decreased the compounds' efficacy in vivo, especially when the microbicide and viral/bacterial inoculums were administered independently (i.e., not premixed) [27, 59] . These results indicate that vaginal microfolds may have a substantial impact on the surface distribution of formulated microbicides administered as liquids, foams, gels, etc. This 3-D vaginal EC model offers researchers a high-throughput in vitro method for evaluating the application, distribution, persistence, and protection of vaginally applied microbicide compounds. In addition, this model may provide additional insights into the mechanisms of STI pathogens and their interactions with human vaginal ECs.
The expression and localization of several important junctional and differentiation markers indicated that the 3-D vaginal EC model contained layers of cell-cell junctions important for tissue architecture and integrity, and that these tissue-like aggregates had polarized and differentiated into sheets of stratified squamous epithelia. One additional group of proteins we chose to examine was a subset of the mucin glycoprotein family previously evaluated in the female lower reproductive tract. Gipson et al. [49] have demonstrated by Northern blot and in situ hybridization that human vaginal tissue expresses MUC1 and MUC4, which correlates with our immunofluorescence data. While the exact role of MUC4 in the vaginal cavity is unknown, MUC1 has been implicated as an 624 extremely important molecule that creates a critical barrier in the female reproductive tract and a variety of other epithelial tissues [47, 48] . The increased immunofluorescence of MUC1 in our 3-D vaginal EC model compared to monolayers of the same cell line indicates our model may possess adhesive and nonadhesive cell surface properties that could greatly influence microbicide distribution and host-pathogen interactions. Interestingly, both MUC1 and MUC4 were found to localize primarily in the folds and crevices of our 3-D vaginal EC model; this was also the location where most secretory/mucus vesicles were observed by SEM analysis.
While physical barriers like tight junctions and mucin proteins play an important role in pathogen defense, the innate immune responses of vaginal ECs are fundamental for STI and microbicide research [2] . Such responses, are in part, due to the activation of pattern recognition receptors (PRRs), including the most well-characterized family, the TLRs, expressed by genital ECs and immune cells [1, 9, 10, 22] . These cells are capable of responding to these stimuli by sending signals that activate neighboring cells as well as activate and recruit professional immune cells to the vaginal cavity. Activation of these PRRs induces a broad array of antimicrobial molecules and recruits effector cells that lead to pathogen elimination. Therefore the activation of the innate immune system through PRR agonists is a strategy for both eliminating pathogens and mounting specific and robust responses to antigens. In particular, vaginal delivery of TLR agonists capable of eliciting a pathogen-specific or molecule-specific immune response have shown great promise for STI prevention strategies, particularly with HSV-2 [60] [61] [62] [63] [64] [65] . TLRs 2, 3, 5, and 6 have been shown to be highly expressed in immortalized vaginal EC monolayers; we analyzed the 3-D vaginal model for TLR activity and found there was no significant difference in cytokine/chemokine production between this 3-D vaginal EC model and its monolayer counterpart [1] . This result was somewhat anticipated as we did not expect 3-D architecture to greatly influence TLR expression since many suspension cell lines that do not rely on tight cell-cell interactions (e.g., THP-1 cells or U-397) highly express TLRs and are functionally responsive. A recent report showed that the polyanionic class of microbicide compounds could actually interfere with TLR signaling and thus highlights the importance of evaluating TLR-mediated epithelial immune responses following microbicide exposure [10] .
Analysis of the microbicide screening capabilities of our 3-D vaginal EC model was performed using N-9 as our microbicidal test agent. Nonoxynol-9 has been extensively studied in vitro and in vivo because of its antiviral activity and subsequent failures in the clinical pipeline [13, 14] . Many studies have indicated that N-9 is toxic to the vaginal epithelium and can inherently damage the plasma membrane of exposed cells; however, the toxic concentration of this compound has been found to vary greatly between surgical explant models and monolayer or suspension cell lines [16, 17] . Beer et al. examined N-9 toxicity in 127 assays from 5 laboratories that included 11 permanent cell lines and 4 primary cell or tissue types (including a cervical explant model); their results indicated that the cervical explant tissue was significantly more resistant to microbicide toxicity than the various cell lines [16] . This report proposed that this difference was due to the 3-D architecture of the explants; our results further support this hypothesis. While our model did not demonstrate TC 50 levels as high as the explant results at our 1.5 h time point, this exposure time also showed a great deal of interassay variation with the explant tissue described and may suggest additional variability between surgical explants, specifically for short-term exposure studies [16] . When grown in 3-D conditions, our vaginal EC model demonstrated comparable TC 50 levels to that of cervical explant tissue, especially between 4 and 24 h poststimulation [16] .
The significance of this 3-D vaginal epithelial model is the formation of a stratified, squamous epithelium in vitro with cellular proliferation, differentiation, progressive keratinization, and ultimately desquamation of cells that resemble exfoliated cells obtained in vivo. This model, therefore, has the potential to be utilized not only for microbicide screening, but could also be used for STI pathogenesis and/or commensal pathogen studies, to study the effect of exogenous factors such as hormones and growth factors and to better understand the innate immune responses (PAMP recognition, secretion of antimicrobial peptides and defensins, etc.) of this mucosal tissue. In future studies, we believe it will be useful to determine if 3-D vaginal cells are estrogen responsive. In preliminary studies, we have tested a high and low concentration of 17-beta estradiol (within the normally active range of the hormone) and found that there was no significant difference in proliferation, morphology, or cell viability among estrogentreated versus mock-treated cells. Because of the use of other growth factors in the serum-free medium, however, we cannot make any conclusions related to the cells' estrogen responsiveness until a comprehensive analysis is completed. Our future plans also include utilizing this rotary cell culture method to develop additional 3-D models of female reproductive tract mucosal tissues that could potentially aid in the study of ascending STI pathogens, including Chlamydia trachomatis and Neisseria gonorrhea. Additionally, we intend to explore the incorporation of various immune cells (i.e., monocytes, macrophages, dendritic cells, etc.) into our 3-D culture models as these coculture models may help delineate the functional role of each cellular constituent that comprises the female reproductive tract when the various tissues are exposed to other STI pathogens (including HIV), chemical compounds, or bioactive molecules.
